Top news from MedWatch this week
Monday
Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide
Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide
Tuesday
Sandoz severs ties with European CMO – Dicillin permanently withdrawn from market
Denmark: Violation of good manufacturing practice is source of contaminated antibiotic
Wednesday
Owners inject EUR 100m into WS Audiology
Danish pension fund argues for capping Genmab CEO’s pay
Thursday
Watchdog looking into Novo Nordisk sponsorship of patient group
Danish health minister to answer questions about Novo Nordisk sponsorship of patient group
Friday
Former GN chair says there have been no acquisition signs from Demant owner
CHMP recommends nine drugs in March
Coloplast challenges its biggest catheter competitor in clinical contest
